semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Dyslipidemia Subjects with a Body Mass Index (BMI)≤ 35 kg/m2 Subjects with the following lipid parameters at Visit 1 (screening visit) and Visit 3 (diet stabilization period) HDL-C ≤ 40 mg/dL (Men) and ≤ 50 mg/dL (Women) TG ≤ 500 mg/dL LDL-C ≤ 190 mg/dL Subjects who are generally healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead ECG  Females who are pregnant or breast-feeding AST, ALT or total bilirubin ≥ 2.0 x ULN at Visit 1 (screening visit) or Visit 3 (diet stabilization period) Serum thyroid stimulating hormone (TSH) and levothyroxine (T4) outside of the central laboratory reference range at the screening visit Medical history of diabetes mellitus or two fasting serum glucose measurements > 126 mg/dL at the screening visit Subjects with hypertension, or two blood pressure measurements ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic at the screening visit History of drug or alcohol abuse within 12 months of the screening visit Use of medications defined in the protocol within six-weeks prior to the screening visit and throughout the study Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol within four weeks of the screening visit and throughout the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Atrial Fibrillation Documented paroxysmal PAF: PAF diagnosis, 2 episodes of PAF within the last 3 months, at least 1 episode of PAF must be documented Age 18-75 Documented effectiveness failure of at least 1 AAD including beta-blockers  AAD usage < 3 half life periods (except beta-blocker) LA size > 55 mm LA thrombus Previous LA ablation/surgery, structural heart disease, heart failure class III-IV Hypertrophic cardiomyopathy Mitral prosthesis Unstable angina Uncontrolled hyperthyroidism Stroke or TIA within 6 months Myocardial infarction within 2 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Heart Failure Patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction ≤40%), were >18 years of age, and were on stable optimal medical heart failure therapy excluding the use of beta-blockers within the previous 30 days   Patients were excluded for active viral myocarditis; hemodynamically significant valvular heart disease; hypertrophic cardiomyopathy, peripartum cardiomyopathy; contra-indications to beta-blockers (asthma or obstructive airway disease requiring scheduled bronchodilators or inhaled steroids), resting heart rate <55; supine blood pressure <85/50; second or third degree heart block); concomitant use of beta-agonists, beta-antagonists, or anti-arrhythmics; unstable angina; myocardial infarction or bypass surgery within 3 months; or significant renal insufficiency (creatinine >2.5 mg/dL), liver disease (transaminase levels > 3 fold above laboratory normal), or anemia
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 2 Diabetes Mellitus male or female 18-65 years of age; 2. type 2 diabetes based on the American Diabetes Association criteria; 3. HbA1c = 6.5-9.0% while on diet alone or diet plus sulfonylurea (or meglitinides) therapy; 4. no history of thiazolidinediones, insulin, ACE inhibitor or AII-receptor blockade therapy; 5. taking no medications known to affect glycemic control or endothelial function, unless the medication has been stable for at least 3 months; 6. blood pressure equal or below 140/90 mmHg; 7. not pregnant and willing to take appropriate contraceptive measures if capable of becoming pregnant; 8. serum creatinine below 1.7 mg/dl in female and 1.8 mg/dl in males; 9. ALT (SGTP) or AST (SGOT) less than 2 times the upper limit of normal for the laboratory and absence of clinical signs or symptoms of liver disease; 10. hematocrit > 34% in females and >35% in males; 11. normal thyroid function; 12. no evidence of coronary heart disease (by history or EKG) or moderate to severe congestive heart failure (NY Heart Association Cardiac Class III or IV); 13. no history or the presence of any clinically significant or unstable medical condition that makes the subject unlikely to complete the study in the opinion of the PI; and 14. absence of any condition or situations which would preclude adherence and completion of the protocol; 15. the ability to give voluntary informed consent  Subjects were excluded from study if they had ever received insulin, metformin, TZDs, exenatide or DPP IV inhibitor. 2. All subjects were free of cardiovascular, renal or major organ disease, as determined by medical history, physical examination, screening blood chemistries, complete blood cell count, and electrocardiogram
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperglycemia renal transplantation (deceased or living donor) for the standard immunosuppression of our center, consisting of tacrolimus, mycophenolate mofetil or mycophenolic acid, dexamethasone/prednisone triple therapy informed consent of the patient  patients with type 1 or type 2 diabetes allergy against long-acting insulin
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Dyspnea age > 18 presenting complaint of shortness of breath or dyspnea  prisoners pregnant women shortness of breath clearly secondary to another diagnosis (i.e. trauma)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cystic Fibrosis cystic fibrosis disease with rhDNase treatment  Acute push of the bronchopulmonary attack or hospitalization for treatment of the disease during 2 weeks previous Exposure to a antibiotherapy or treatment by corticoids
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-85.0,  Hypercholesterolemia Coronary Artery Disease Patients with dyslipidemia as defined by any of the parameters HDL-C < 50 mg/dL LDL-C ≥ 140 mg/dL LDL-C ≥ 100 mg/dL and cholesterol-lowering treatment is necessary in accordance with the investigator's judgement Patients who passed three months or more after acute myocardial infarction Patients who passed one month or more after unstable angina Patients who passed one month or more after PCI Patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial  Patients with any allergy to pitavastatin or atorvastatin Patients with familial hypercholesterolemia Patients receiving pitavastatin Patients with severe hypertension Patients with renal disorders or undergoing dialysis Patients with hepatobiliary disorders Patients with hepatobiliary disorders Patients with family history of hypothyroidism or muscular dystrophy Patients with history of drug-induced hepatic disorder Drug abuser or dipsomaniac
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Myocardial Fibrosis Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy 2. Able to swallow pills 3. No prior septal reduction therapy 4. Negative serum or hCG pregnancy test  Unable or unwilling to perform treadmill cardiopulmonary exercise test 2. Prior surgical myectomy or alcohol septal ablation 3. Known or suspected infiltrative or glycogen storage disease 4. Significant coronary artery disease, defined as atherosclerotic coronary artery narrowing >70% of the luminal diameter by coronary angiography 5. Severe obstructive pulmonary disease, defined as forced expiratory volume in 1 second (FEV1) <50% of predicted. 6. Prior intolerance or adverse reaction to aldosterone receptor antagonist. 7. History of hyper or hypoaldosteronism 8. Baseline serum potassium >5.0 mmol/L. 9. Calculated creatinine clearance <30 ml/min using Cockcroft-Gault formula. 10. Pregnant or breast feeding 11. Poorly controlled systemic hypertension, defined as systolic blood pressure ≥150 mmHg or diastolic pressure ≥100 mmHg, during 2 clinic visits. 12. Known conditions associated with elevated serum concentrations of (e.g., chronic liver disease, diabetes mellitus, tumors, pulmonary fibrosis, bone and rheumatoid diseases, extensive wounds) or PINP (e.g., alcoholic liver disease, metabolic bone disease, thyroid disorders), including recent trauma (≤2 weeks) or surgery (≤6 months) 13. Taking drugs known to directly influence collagen metabolism including, amiodorone, ACE or angiotensin II inhibitors, aldosterone antagonists, statins, glucocorticoids and estrogens 14. Patients with ICDs/pacemakers will be recruited in the study, but will be excluded from the CMR component
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Hypercholesterolemia Type 1 DM Age > 18 years Subjects diagnosed with type 1 DM (diagnosed based upon history of ketoacidosis, proven insulin dependence, absent C-peptide and or positive autoantibody profile (such as anti-GAD etc.) Stable A1C < 8.5% BMI < 31 Type 2 DM Age > 18 years Subjects diagnosed with type II DM (diagnosed as adult onset, not-insulin dependent and not on insulin) Stable A1C < 8.5% BMI < 31  History of active, unstable cardiovascular disease (including MI, CHF, Stroke, Angina, CABG, stenting/PTCA, peripheral vascular disease, intermittent claudication) Pregnancy, nursing or likely to get pregnant during the course of the study (not on oral contraceptives and premenopausal) Chronic Kidney Disease (creatinine > 2.0) Liver function test abnormalities, not previously worked up (AST or ALT >4x upper limit of normal) Active substance abuse including alcohol History of severe Hypertriglyceridemia (untreated TG > 500) and on therapy Use of agents that interfere with cholesterol absorption (such as fiber, resins etc.) which can not be discontinued for the duration of the study Actively enrolled in a weight loss program or following a special diet ( e.g.: Atkins diet) History of malignancy <5y History of Rhabdomyolysis and Myopathy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hypertension Hypertension, defined as systolic blood pressure greater than or equal to 130 but less than 160 mm Hg and diastolic blood pressure greater than or equal to 85 but less than 110 mm Hg Must have any two of the following 1. Abdominal obesity, defined as a waist circumference greater than 40 inches in men and greater than 35 inches in women 2. High-density lipoprotein (HDL) cholesterol level of less than 40 mg/dL in men and less than 50 mg/dL in women 3. Fasting triglycerides greater than or equal to 150 mg/dL 4. Fasting glucose level of 100-125 mg/dL  Significant hypertension (greater than 160/110 mm Hg) Isolated systolic hypertension Diseases requiring treatment with diuretics or angiotensin-converting enzyme (ACE) inhibitors Cardiovascular disease (history of heart attack, stroke, heart failure) Hypersensitivity to HCTZ or ACE inhibitor Type 1 or type 2 diabetes Hypokalemia Peri-menopause (symptom onset within 1 year) Pregnant or breastfeeding Secondary causes of hypertension
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Volunteer Fatigue Depression To be included, participants must meet the following Healthy, 18 years of age or older Speak and understand the English language  Participants with any one of the following will be excluded Inability to provide informed consent for the study Are unwilling or unable to cooperate with the study procedures or travel to NIH for the procedures Have a confirmed medical condition causing clinically significant fatigue symptom (e.g. congestive heart failure, cancer actively receiving therapy, sleep disorders) Currently taking medications that cause fatigue (e.g. diuretics, beta blockers, narcotics) Working late evening and night shifts within the past month Have severe psychiatric conditions (e.g. major depressive disorder, bipolar disorder, anxiety disorder, schizophrenia, drug and/or addiction abuse or dependence) Report consuming more than 300mg of caffeine containing beverages (approximately 4 cups of coffee or 8 cups of soda or tea) or food (approximately 1 lb of chocolate) within 24 hours Reports consuming more than 2 servings of alcohol containing beverages every day and with detectable blood alcohol content (BAC) using breath analyzer (greater than 1 mg/dL of BAC) Pregnant or lactating women
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 25.0-75.0,  Hypercholesterolemia With Type2DM Age: 25yrs~75yrs Fasting TG <400mg/dL, LDL-C ≥130mg/dL onths > Diagnosed Type2 DM, With OAD, HbA1c ≤ 10.0% or First Diagnosed Type2 DM, 6.5%≤HbA1c≤10.0%  Type1 DM, Gestational diabetes Patient need to treat with Insulin Patient with operational treatment for severe diabetic complication Uncontrolled Hypothyroidism Unstable angina, MI, transient ischemic attack(TIA), Stroke, PCI, Heart Failure within 3 months (NYHA class4) Severe Hypertension (SBP ≥ 180 or DBP ≥ 110mmHg) Renal disorder (Serum creatinine ≥ 2.0mg/dL) Hepatic disorder (AST or ALT ≥ 2.5 X UNL) Creatinine Kinase > 2.5 X UNL Gravida or lactation phase
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Proteinuria Diabetic Nephropathy Chronic Kidney Disease CKD stage 1 patients Older than 18 years of age Type 2 Diabetic patients Proteinuria  History of coronary artery disease Smokers Taking statins or renin-angiotensin blockers